Meeting
2015 ASCO Annual Meeting
CheckMate 214: A phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in patients with previously untreated metastatic renal cell carcinoma.
Authors
Hans J. Hammers
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
Hans J. Hammers , Elizabeth R. Plimack , Cora Sternberg , David F. McDermott , James M. G. Larkin , Alain Ravaud , Brian I. Rini , Padmanee Sharma , Prabhu Bhagavatheeswaran , Paul Gagnier , Robert Motzer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT02231749
Citation
J Clin Oncol 33, 2015 (suppl; abstr TPS4578)
DOI
10.1200/jco.2015.33.15_suppl.tps4578
Abstract #
TPS4578
Poster Bd #
248a
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).
First Author: Tian Zhang
Poster
2020 ASCO Virtual Scientific Program
PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).
First Author: Tian Zhang
Poster
2020 Genitourinary Cancers Symposium
PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).
First Author: Tian Zhang
Poster
2019 ASCO Annual Meeting
PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).
First Author: Tian Zhang